In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Optimizing Outcomes with Permissive Brainstem Dosing and Anatomic Considerations in the Radiosurgical Treatment of Trigeminal Neuralgia

    Final Number:

    Michael Zhang MD; Matthew Schoen; Layton Lamsam BS; Geoff Appelboom MD, PhD; Scott G. Soltys MD; John R Adler MD; Steven D. Chang MD

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: CyberKnife stereotactic radiosurgery (SRS) for trigeminal neuralgia (TGN) administers non-isometric, conformational high-dose radiation to the root entry zone, with possible post-procedural numbness from excessive brainstem exposure. We evaluated outcomes from two treatment plans differing in their maximum brainstem dose.

    Methods: A retrospective, single-institution review of 91 TGN patients treated with CyberKnife from January 2005-May 2007 (Plan A, N=47) and January 2009-August 2013 (Plan B, N=44) was conducted. Plan A (vs B) aimed for a maximum brainstem dose of 40 vs 25 Gy, respectively, both in one fraction with 75 Gy to the 100% isodose line. Primary outcome was self-reported pain control. Secondary outcomes included change in Barrow Neurologic Institute (BNI) pain and numbness scores. Pre-pontine nerve length, maximum brainstem dose, and treatment history were additionally recorded for their predictive contribution by matched-cohort regression.

    Results: Patients were followed for a mean of 23 months, and 62% were naïve to treatment. Plans A and B exhibited treatment failure, durable improvement, and pain recurrence in 6.4% vs 18.0% (p=0.084), 68.1% vs 36.4% (p=0.002), and 25.5% vs 45.5% (p = 0.047), respectively. Mean BNI pain scores improved for 74.5% vs 61.3% (p=0.18), while BNI numbness scores increased for 45.2% and 72.7% (p=0.042). Cohorts differed in baseline nerve length at 10.1 mm vs 7.5 mm (p<0.001). Regression analysis on cohorts matched by length demonstrated that treatment plans allowing higher brainstem maximum dosing was associated with pain improvement (p=0.05), and univariate analyses showing longer nerve length predicted decreased numbness (p=0.03). Furthermore, under Plan A, improvement was predicted by age, prior decompression and prior SRS (AUC=0.82).

    Conclusions: These outcomes show a higher maximum brainstem dose constraint may result in better pain control without worsening rates of facial numbness. Future application of CyberKnife SRS may consider higher doses in patients with longer nerves and no prior treatment history.

    Patient Care: These findings report how variations in treatment planning and heterogeneity in individual patients can differentially influence the likelihood of pain control following radiosurgery, while minimizing complications.

    Learning Objectives: 1) Appreciate isodose-planning adaptations in high-dose, confined spacing of TGN treatment 2) Optimize patient selection based on history, dosing, and anatomic considerations 3) Consider the permissive brainstem dosing to safely improve pain-control

    References: PMID: 14519214, 15913285, 28173233, 16682146, 19165080

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy